MedTrace Logo

A PET Study in Healthy Volunteers

NCT01424449 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2012-12-17

No results posted yet for this study

Summary

This will be an open label, non-randomised \[11C\]PHNO PET study using healthy male volunteers. Each volunteer will undergo 4 \[11C\]PHNO PET scans to allow for further characterisation of this radioligand and examine the effects of \[11C\]PHNO mass carry-over and displaceable binding in the brain. This study aims to obtain data from 6 evaluable subjects.

Conditions

  • Depressive Disorder

Interventions

RADIATION

[11C]PHNO

examine the effects of \[11C\]PHNO mass carry-over and displaceable binding

DRUG

Aripiprazole

A 4th scan will follow a 15mg dose of aripiprazole (a D2/D3 compound which allows the highest clinically acceptable blockade of central D2/D3 receptors)

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01424449 on ClinicalTrials.gov